Top Stories

Almirall

Almirall edificio id

In Europe 18th September 2023

EMA gives thumbs up to Almirall’s atopic dermatitis medicine Lebrikizumab

Bankinter: Ebglyss (lebrikizumab) receives positive opinion from the European Medical Agency’s advisory committee. The Target Price is raised from €9.50/share to €10/share . The positive opinion of the committee has to be reviewed by the European Commission, which issues the marketing authorisation. This step could take 2-3 months and, if ratified, the commercial launch of Ebglyss will be almost immediate. The drug is a treatment for moderate to severe atopic…

Almirall edificio id

In Spain 8th September 2023

Almirall’s rebound from June lows of almost 40% leaves fastest indicators overbought

Renta 4| The price has violently broken the downward trend line from the highs of July 2021, while confirming important bullish divergences in its slow indicators. Moreover, the monthly indicators have started a bullish process, which is often accompanied by additional upward pressure in the medium/long term. The price presents a key reversal support level, between the lows of last June at €7.15 and the crossing of the main bullish…

Almirall edificio id

In Spain 4th September 2023

Almirall acquires rights to distribute Alzheimer’s treatment in Spain for an initial €45 million

Bankinter| Laboratorios Almirall (ALM) has acquired the rights to distribute a product to treat Alzheimer’s disease in Spain. The agreement gives Almirall exclusive rights to a transdermal patch containing Rivastigmine to treat Alzheimer’s disease. The transaction has been closed for an upfront payment of €45 million and provides for additional potential compliance payments of up to €15 million. Assessment: Positive news, the company has been looking for acquisitions to strengthen…

Almirall

Spanish economy 22nd December 2021

Positive Results From Phase III Study For Lebrikizumab; Almirall Will Seek Commercial Authorisation

Bankinter | Lebrikizumab is a new treatment being developed for atopical dermatitis licensed by Eli Lilly to Almirall (ALM). In the third study in Phase III, it has shown to have had a significant improvement on the skin, relieving itching for people with this ailment when combined with topical corticosteroids. The study has met all the primary valuation criteria and the principal secondary ones, and has a security profile consistent…

Almirall

Markets, Spanish Small & Mid Caps 5th June 2019

Almirall: recent revaluation (+46%) reduces potential 13.1%

I. Isardo (Link Securities) | Almirall (ALM) is a vertically integrated international pharmaceutical group which focuses on the purchase, production, storage, commercialisation and mediation in the sale of specialities and pharmaceutical products and of all types of raw materials used in the production of specialities and pharmaceutical products.

Almirall

Ibex, Markets 16th May 2018

Almirall: recommendation raised from Sell to Neutral

Bankinter | Almirall Q1’18 results were better than expected, with sales of 189.3 million euros (-0.1%); Ebitda of 58 million (+5.4%); Net Attributable Profit of 30.9 million (+57.1%) and net debt of 150 million euros. Finally, the DN/PN ratio has reached 7.4%.

No Picture

Markets 6th May 2014

Almirall, Campofrío and Sacyr, the most recommended values in the Spanish market

MADRID | By Jaime Santisteban | Almirall, Campofrío and Sacyr are the most recommended values in the Spanish market, according the market consensus. Repsol turned down the offer to renew its two seats in the YPF ‘s board on Tuesday, and fixed its eyes in Norway instead. Also, unemployment in Spain reportedly dropped by 111,565 people in April. “Although this means a turning point in the Spanish economic recovery, the country remains in the deep well,” The Corner senior analyst Fernando G. Urbaneja explains.